Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: Insights From Clinical Practice Into Scoring Criteria, Histologic Subtypes, and Genomic Characteristics Across Disease Sites.
HER2 testing variations in bladder cancer are now characterized, supporting precise patient selection for emerging HER2-targeted drugs.
This Arch Pathol Lab Med study from Johns Hopkins characterizes HER2 expression and genomic status across urothelial carcinoma sites, revealing scoring pitfalls and site-specific variations relevant to HER2-targeted therapy selection (trastuzumab deruxtecan, disitamab vedotin). The findings directly inform precision HER2 assessment as HER2-targeted therapies enter urothelial carcinoma guidelines.
What the study was
- Study design
- Retrospective clinical-pathologic correlation study
- Population
- Urothelial carcinoma patients with HER2 assessment at Johns Hopkins
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Archives of pathology & laboratory medicine
Why it surfaced
Arch Pathol Lab Med; HER2 scoring in urothelial carcinoma is near-term implementable as HER2-targeted therapies enter bladder cancer management; Johns Hopkins pathology.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.